Please replace lines 17-19 on page 11 with the following paragraph:

Q2 --**Figure 4** shows increased anxiety-like behavior of mutant animals in the elevated plus maze and open field tests.--

Please replace line 20, page 11 to line 2, page 12 with the following paragraph:

Q3 --**Figure 4A** shows the percentage of time spent in the open arms (**, $p<0.005$) and number of entries to the open arms (*, $p<0.02$) were significantly less for the male mutant mice than for the wild type controls (control n=7, mutant n=7; mean +SEM).--

Please replace lines 3-11 on page 12 with the following paragraphs:

Q4 --**Figure 4B** shows the percentage of time spent in the open arms (*, $p<0.03$) and number of entries to the open arms (*, $p<0.03$) were significantly less for the female mutant mice than for the wild type controls (control n=9, mutant n=12; mean +SEM).

Figure 4C shows locomotor activity in the EPM was not different between control and male mutant animals as measured by total closed arm entries and total arm entries.

Figure 4D shows locomotor activity in the EPM was not different between control and female mutant animals as measured by total closed arm entries and total arm entries.

Figure 4E shows no difference was found in anxiety-like behavior as measured in the light/dark box experiment for time spent in the light portion of the box.

Figure 4F shows no difference was found in anxiety-like behavior as measured in the light/dark box experiment for the number of transitions between the light and dark portions.

Figure 4G shows increased anxiety-like behavior of mutant mice in the open field test as measured by the time spent in the inner squares of the open field apparatus (*, $p<0.05$, control n=5, mutant n=7, mean +SEM).

Figure 4H shows increased anxiety-like behavior of mutant mice in the open field test as measured by the percent of total crossings occuring in the inner squares of the open field apparatus (**, $p<0.01$, control n=5, mutant n=7, mean +SEM).--

Please replace lines 6-9 on page 13 with the following paragraph:

Q5 --**Figure 6** shows cardiovascular responses to intravenous infusion of 1.0 ug UCN in wild type (n=5) and mutant mice (n=3) (white bar). Note the remarkable muted response of mutant mice to the UCN injection (*** $p<0.005$). *Crfr2* mutant mice also received a second infusion of sodium nitroprusside (0.8 ug in 100 ul of 0.9% saline) following recovery of arterial pressure from the UCN infusion (black bar). The mean arterial pressure (MAP) was determined from the blood pressure tracings.--

IN THE CLAIMS:

Please amend claim 20 as follows:

Q6 20. (amended) A method of inhibiting angiogenesis in a target tissue comprising the step of administering a Corticotropin Releasing Factor Receptor 2 (CRFR2) agonist to said target tissue, wherein said CRFR2 agonist inhibits angiogenesis in said tissue.

{Please amend claim 21 as follows:}

21. (amended) The method of claim 20 wherein said CRFR2 agonist is selected from the group consisting of urocortin and corticotropin releasing factor.